Evidation Health — San Mateo, California

Evidation Health is a clinical research site located in San Mateo, California, United States 94401.

Crixeo Clinical Trials Trust Score: 21/100 (FAILING). This profile has not yet been claimed by the site owner.

Evidation Health has participated in 17 clinical trials with 1 currently active.

Therapeutic areas: Diabetes, Influenza -Like Illness, Influenza A.

Sponsors: Evidation Health, Omada Health, Inc., Janssen Scientific Affairs, LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in San Mateo

Browse all research sites in California · View every site in San Mateo

• Mills Peninsula Hospital
• Mills Health Center
• San Mateo County AIDS Program
• Novo Nordisk Investigational Site
• UCSF Cancer Center San Mateo
• Mills-Peninsula Health Services
• San Mateo Medical Center
• Research Site
• Pfizer Investigational Site
• Premier Plastic Surgery
• GSK Investigational Site

Sponsor Feasibility Report

Trust Score: 21/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Evidation Health?

Evidation Health has a Crixeo Trust Score of 21/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Evidation Health conducted?

Evidation Health has 17 clinical trials on record, with 1 currently active. Their work covers Diabetes, Influenza -Like Illness, Influenza A.

Is Evidation Health accredited by Crixeo Clinical Trials?

Evidation Health has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Evidation Health?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.